Physician profile
Ashraf Mansour
NPI 1952402398
$17,345.61
in general payments reported to CMS, 2019-2025
41 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,856 · 2020: $1,564 · 2021: $2,796 · 2022: $5,408 · 2023: $1,813 · 2024: $1,735 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,721.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,419.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Silk Road Medical, INC. | $3,063.18 | 2022 | |
| Philips North America LLC | $1,913.71 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| W. L. Gore & Associates, INC. | $1,258.03 | 2019-2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,100.91 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $913.05 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $647.80 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Novo Nordisk INC | $453.39 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $444.05 | 2019 | |
| Abbott Laboratories | $338.05 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $323.04 | 2019-2021 | |
| Optinose US, INC. | $320.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $305.91 | 2019-2022 | |
| Mannkind Corporation | $288.24 | 2019-2023 | Afrezza |
| Amgen INC. | $278.90 | 2019-2023 | Otezla, Repatha |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $219.46 | 2019-2020 | |
| Lilly USA, LLC | $198.90 | 2019-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $195.71 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $182.27 | 2021 | |
| Penumbra, INC. | $160.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.83 | 2019-2025 | Relistor |
| Novartis Pharmaceuticals Corporation | $135.93 | 2019-2024 | |
| Abbvie INC. | $135.68 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $127.64 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $110.87 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $95.79 | 2022-2024 | |
| Astellas Pharma US INC | $88.27 | 2019-2025 | Veozah |
| Mylan Specialty L.P. | $78.45 | 2020-2022 | |
| Exact Sciences Corporation | $62.35 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $56.59 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $53.93 | 2022-2023 | Hetlioz |
| Gilead Sciences, INC. | $44.35 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.13 | 2022 | |
| Aroa Biosurgery Incorporated | $27.79 | 2022 | |
| Ironwood Pharmaceuticals, INC | $26.17 | 2019 | |
| Phadia US INC. | $24.32 | 2019-2021 | |
| Baxter Healthcare | $20.63 | 2025 | Hillrom - Monarch Airway Clearance System |
| Dexcom, INC. | $17.24 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $16.16 | 2025 | Korlym |
| Circassia INC. | $14.54 | 2019 | |
| Hikma Pharmaceuticals USA | $14.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.